Hibsago (bepirovirsen) Approved in the US for the Treatment of Chronic Hepatitis B (CHB)
Go back to Hibsago (bepirovirsen) Approved in the US for the Treatment of Chronic Hepatitis B (CHB)| GLAXOSMITHKLINE PLC (NYSE: GSK) | Delayed: 50.02 -0.61 (1.2%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $50.63 | 52 Week High | $45.58 | |||
| Open | $50.19 | 52 Week Low | $37.82 | |||
| Day High | $50.45 | P/E | N/A | |||
| Day Low | $49.91 | EPS | $0.00 | |||
| Volume | 3,340,597 | |||||



